Statistics

Total Visits

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)51

Select a period of time:

Number of views in the range

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)30

Views

Views
March 202515
April 20258
May 20251
June 20250
July 20254
August 20250
September 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Hong Kong6
United States5
Brazil2
Canada1
Spain1
 

Top cities views

Views
Hong Kong6
Dallas3
Council Bluffs1
Halifax1
Paulo Frontin1
Pueblo1
São Paulo1